Immunological, Clinical, and Epidemiological Features of Guillain-Barré Syndrome Associated with SARS-CoV-2 Infection

Table 2

Serum systemic autoantibodies in GBS patients according to antecedent event.

		Total ()	GBS-S ()	GBS-V ()	GBS-O ()
Serum systemic autoantibodies	Positive test, (%)	16/25 (64)	8 (88.9)	2 (66.6)	6/13 (43.2)	0.07
	ANAs, (%)	9/25 (36)	4 (44.4)	1 (33.3)	4/13 (30)	0.66
	Nucleolar, (%)	1/9 (11.1)	0/4 (0)	0/1 (0)	1/4 (25)	0.14
	Speckled, (%)	6/9 (66.7)	4/4 (100)	1/1 (100)	1/4 (25)
	Homogenous, (%)	2/9 (22.2)	0/4 (0)	0/1 (0)	2/4 (50)
	ANA titer, median (range)	1/80 (1/80-1/640)	1/80 (1/80-1/160)	1/160 (-)	1/160 (1/80-1/640)	1
	Anti-SSA/Ro60, (%)	10/21 (47.6)	7 (77.8)	2 (66.6)	1/9 (11.1)	0.015
	>20.00 CU, median (IQR)	69.6 (61.6)	59.9 (58.8)	43.3 (-)	34 (-)	1
	Anti-SSA/Ro52, (%)	2/21 (9.5)	2 (22.2)	0 (0)	0/9 (0)	—
	ANCA, (%)	1/15 (6.6)	0/5 (0)	0/2 (0)	1/8 (12.5)	1
	RF, (%)	2/10 (20)	1/5 (20)	0/2 (0)	1/3 (33.3)	1
	aPL, (%)	0/7 (0)	0/5 (0)	0/1 (0)	0/1 (0)	—
Persistent seropositivity, (%)		1/9 (11.1)	1/5 (20) (ANAs)	0/1 (0)	0/3 (0)	—

^aItalic-typed values represent statistically significant differences between GBS-S and GBS-O. GBS-V has been excluded from statistical analysis. Abbreviations: ANAs: antinuclear antibodies; ANCA: antineutrophil cytoplasmic antibodies; aPL: antiphospholipid antibodies; CU: chemiluminescent unit; GBS: Guillain-Barré syndrome; IgG: immunoglobulin G; IQR: interquartile range; O: other antecedents or none; RF: rheumatoid factor; V: vaccine against SARS-CoV-2; S: SARS-CoV-2 infection; SD: standard deviation.